Logo image
Developing DNA vaccines that call to dendritic cells
Journal article   Open access   Peer reviewed

Developing DNA vaccines that call to dendritic cells

Michele A. Kutzler and David B. Weiner
The Journal of clinical investigation, v 114(9), pp 1241-1244
01 Nov 2004
PMID: 15520855
url
https://doi.org/10.1172/JCI200423467View
Published, Version of Record (VoR) Open

Abstract

DNA vaccination is a novel immunization strategy that has great potential for the development of vaccines and immune therapeutics. This strategy has been highly effective in mice, while less immunogenic in nonhuman primates and humans. Enhancing DNA vaccine potency remains a challenge. It is likely that APCs, and especially DCs, play a paramount role in the presentation of vaccine antigen to the immune system. A new study reports the synergistic recruitment, expansion, and activation of DCs in vivo in a mouse model through covaccination with plasmids encoding macrophage inflammatory protein-1α (MIP-1α), fms-like tyrosine kinase 3 ligand (Flt3L), and the DNA vaccine. Such cooperative strategies delivering vaccine in a single, simple platform result in improved cellular immunity in vivo, including enhanced tetramer responses and IFN-γ secretion by antigen-specific cells.

Metrics

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Medicine, Research & Experimental
Logo image